Lupus & antiphospholipid syndrome
Treatment patterns, treat-to-target goals and clinical outcomes of patients with active lupus nephritis: real-world evidence from a multicentre cohort study
Authors' conclusion
In a multinational cohort of patients with active LN receiving non-biologic conventional therapy, the attainment of renal responses, LLDAS, and REM was low, while damage accrual was prevalent.
Study context
- Population
- Adults with active lupus nephritis (LN) (SLEDAI-2K proteinuria >0.5 g/24 h or >0.05g/mmol), ≥2 visits, no biologic exposure, on non-biologic conventional therapy; multinational Asia-Pacific lupus cohort435 (37%) biopsied
- Participants
- 1,180 adults
- Outcome
- Attainment of treatment goals (mCRR, mPERR, LLDAS, DORIS remission) and organ damage accrual over time after first visit with proteinuria
Methodological detailsmulticentre, multinational, real-world
- Multicentre
- Multinational
- Real-world
Main finding
As reported in the abstract
Attainment at least once during follow-up (median 2.7 [IQR 1.0, 5.0] years)
mCRR
46%
mPERR
55%
Lupus low disease activity state (LLDAS)
60%
Remission (REM)
46%
Observational data: associations, not effects.
Further findings
Timing of attainment
- mCRR and mPERR attainment highest at year 2; LLDAS and REM attainment gradually increased over time
New organ damage accrual
- By year 1
- 11%
- By year 5
- 33%
Biopsy class III/IV among biopsied
- Class III/IV
- 242 (56%)
Original publication
Treatment patterns, treat-to-target goals and clinical outcomes of patients with active lupus nephritis: real-world evidence from a multicentre cohort study. Arthritis Res Ther. Published 18 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →